A real-time reverse transcriptase-polymerase chain reaction (RT-PCR) method for detection of cytokeratin 20-positive cells in blood characterized by two novel features was developed and tested on 99 patients with colorectal cancer, 110 with breast cancer, and 150 healthy subjects. To optimize the specificity and sensitivity of the method, two novel features were used. First, a primer overlapping two adjacent exons was generated to inhibit nonspecific amplification both in healthy donors and cancer patients; second, a non-end-point first-round amplification was used to increase sensitivity. The number of firstround cycles was chosen to reach the highest level of sensitivity while conserving quantitative characteristics. PCR efficiency increased from 88.9% in singleround RT-PCR to 99.0% in nested real-time RT-PCR. To establish sensitivity and specificity of the method, HT29 cells were serially diluted with normal blood. Detection limit improved from 100 HT29 cells (singleround RT-PCR) to 1 to 10 cells (nested real-time RT-PCR) per 3 ml of whole blood. None of the healthy subjects was positive, whereas 22 and 29% of all colorectal and breast cancer patients, respectively, had cytokeratin 20 cell equivalents in blood. The association between cytokeratin 20 cell equivalents and metastasis was statistically significant for breast (P ؍ 0.026) but not colorectal cancer patients (P ؍ 0.361). Negativity of all 150 healthy controls examined confers diagnostic potential to the method. Cytokeratin mRNAs are potential markers for detection of epithelial cells in blood. Several reports indicate that cytokeratin 20 (CK20) mRNA in blood acts as a specific cancer cell marker in patients with frequent cancer forms of epithelial origin such as breast 1-5 and colorectal cancer.6 -9 Many breast cancer patients develop metastasis after locoregional and systemic treatment even in the absence of dissemination as assessed by conventional diagnostic tools. Approximately 30 to 50% of colorectal cancer patients who have undergone curative resection have recurrences with fatal outcome.10,11 Most recurrences occur in patients with TNM (tumor, nodes, and metastases) stage II and III cancers, but patients with stage I lesions also have appreciable risk. In these patients, cancer cells were disseminated either before or during surgery of the primary tumor.12-14 Although the relationship between circulating tumor cells and the development of recurrent cancer is not fully understood, it is generally assumed that enhanced dissemination of cancer cells in blood contributes significantly to the development of metastasis. [15][16][17] The detection of circulating metastatic cells would be of great value for the assessment of the metastatic risk.18 Currently, the most powerful prognostic information in cancer patients is obtained from conventional histological assessment of regional lymph nodes. 19 -23 Because 20 to 30% of colorectal cancer patients without metastasis in lymph nodes die from distant metastases or local recurrence within 5 years 24...